12 results about "Adrenoceptor agonist" patented technology

Disclosed are methods and compositions for treatment of androgenetic alopecia, telogen effluvium, hair shedding, and / or other forms of alopecia. The method involves: a) topically applying a composition including an androgenic agonist, an ADRB2- agonist, and / or a trace amine-associated receptor (TAAR) agonist; or b) orally administering a composition including an androgenic agonist, an adrenoceptor beta 2 (ADRB2) agonist, and / or a TAAR agonist; or c) administering a composition including an androgenic agonist, an adrenoceptor beta 2 (ADRB2) agonist, and / or a TAAR agonist via a transdermal, subdermal, or subcutaneous vehicle.

There is provided herein a method of treatment comprising: (i) a first treatment cycle comprising administration of a therapeutically effective amount of a therapeutic agent, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the therapeutic agent directly or indirectly induces muscle wasting; and (ii) a second treatment cycle following the discontinuation of the first treatment cycle, wherein the second treatment cycle comprises administration of a therapeutically effective amount of a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, to the subject, wherein the first and second treatment cycles are within the same therapeutic intervention.

This specification provides a β2-adrenergic receptor agonist or a pharmaceutically acceptable salt thereof for use in the treatment and / or prophylactic care of hyperglycemia or a disorder characterized by hyperglycemia, wherein the treatment and / or prophylactic care further comprises the administration of (a) insulin or a therapeutic insulin derivative, or (b) a therapeutic agent that stimulates the release of insulin.

Described herein are compositions, devices, and methods useful for treating (reversing) and / or preventing fentanyl overdose resulting in respiratory failure or airway obstruction (FIVCC). Compositions are provided that include optimized amounts and / or ratios of two active ingredients, including: an alpha 2 adrenergic receptor agonist (e.g., lofexidine, dexmedetomidine, clonidine) and a short acting mu opioid receptor antagonist (e.g., naloxone); an alpha 2 adrenergic receptor agonist and a long acting mu opioid receptor antagonist (nalmefene); and an alpha 2 adrenergic receptor agonist and a fentanyl opioid analgesic. Methods and devices for concurrent delivery of combined active ingredients are also provided.

The present disclosure relates to novel alpha2 adrenergic receptor (alpha2AR) agonists and uses thereof. Specifically, the present disclosure relates to imidazole-containing compounds, in particular to compounds represented by formula (I-A), formula (I-B), formula (I-C), formula (I-D) or formula (II). The compounds are useful as peripheral selective alpha2AR agonists for the treatment or prevention of related diseases.

A method for preparing an intermediate of an adrenergic receptor agonist. The method comprises the following steps: cyclizing the compound of formula E1 or the compound of formula E2 and the compound of formula F0 to obtain the compound of formula C, where R1 is methyl, ethyl, isopropyl, propyl, tert-butyl, or butyl; R3 is H, Cl, F or Br; and L1 and L2 are each individually a leaving group. The method uses easily available raw materials, avoids the use of toxic and harmful reagents, is mild in terms of reaction conditions, is simple to operate, achieves a substantial improvement in yield and reduction in cost, and is more favorable for commercial production.

The present invention relates generally to methods of assessing platelet function, e.g., for assessing platelet function from a sample of a subject. These methods may be used to identify a subject based on the responsiveness or sensitivity of platelets of the subject to a platelet activating substance, such as collagen-related peptide (CRP), or thrombin, ADP, thromboxane A2, or adrenergic receptor agonist. The invention also provides a method for evaluating the level of CD36, the level of GPVI and / or the age of a subject in platelets of the subject as a functional indicator of the platelets of the subject. These methods can be used to predict the responsiveness of a subject to anti-platelet therapy, and thus can be part of a therapeutic method.

Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.

The present invention relates to a transdermal composition comprising a compound selected from the group comprising formoterol, salbutamol, salmeterol, fenoterol, mixtures thereof or salts thereof, and dimethylsulfoxide. The present invention further relates to a composition comprising a compound selected from the group comprising salbutamol, clenbuterol or salts thereof, and comprising at least one of water or a monohydric alcohol.

The invention discloses a sedative pharmaceutical composition special for proton therapy, the sedative pharmaceutical composition has a double-layer skeleton structure, the outer layer comprises a benzodiazepine derivative subjected to cyclodextrin inclusion treatment, and the inner layer comprises an alpha2-adrenergic receptor agonist wrapped by PLGA microspheres. The sedative pharmaceutical composition special for proton therapy can realize quick release-slow release biphasic regulation, the outer quick release layer takes effect within 5 minutes, the inner slow release layer keeps sedative for 2-4 hours, and the requirements of all treatment stages are met; meanwhile, the analgesic effect of the alpha2-adrenergic receptor stimulant is combined, so that the addiction of traditional opioids is avoided; and a pH-responsive nano-carrier (the disintegration threshold pH is 5.5 + / -0.2) is adopted, is only triggered and released in an acidic microenvironment of a proton treatment target region, and acts synchronously with an irradiation region.

The invention provides a liquid pharmaceutical composition comprising: a) at least one long-acting muscarinic receptor antagonist (LAMA) selected from the group consisting of glycopyrronium bromide, ipratropium bromide, umiclidium bromide, and revefenacin; b) at least one long-acting adrenoceptor agonist (LABA) selected from the group consisting of formoterol fumarate, salmeterol xinofoate; alformoterol tartarate, and vilanterol trifenate; and c) at least one inhaled corticosteroid (ICS) selected from the group consisting of beclomethasone dipropionate, budesonide, ciclesonide, fluticasone furoate, and fluticasone propionate; and wherein the composition is in the form of a solution for aerosolization, as well as methods and devices for use of the composition.

Described herein is a crystalline form of a hemihydrate of the β-3 adrenergic receptor agonist vibegron. The disclosure also relates to preparations of the crystalline form, pharmaceutical compositions thereof, methods of making the crystalline form, and methods of using the crystalline form in the treatment of overactive bladder.